DYAI Long Put Strategy
DYAI (Dyadic International, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies. This technological foundation drives their research, development, and commercial endeavors, focusing on the creation and manufacturing of various human and animal vaccines and pharmaceutical products. These offerings span a wide range of biological therapeutics, including virus-like particles (VLPs), antigens, monoclonal, bi-specific, and tri-specific antibodies, Fab antibody fragments, Fc-fusion proteins, biosimilars, biobetters, and diverse therapeutic enzymes and proteins. A key pipeline asset is DYAI-100, a SARS-CoV-2-RBD antigen vaccine candidate. This candidate is currently slated for a first-in-human Phase 1 clinical trial, with the objective of establishing proof of concept for the development of next-generation, multivariant COVID-19 vaccine candidates.
DYAI (Dyadic International, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $29.2M, a beta of 1.17 versus the broader market, a 52-week range of 0.65-1.35, average daily share volume of 257K, a public-listing history dating back to 2008, approximately 6 full-time employees. These structural characteristics shape how DYAI stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.17 places DYAI roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a long put on DYAI?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
Current DYAI snapshot
As of June 30, 2026, spot at $0.91, ATM IV 20.50%, IV rank 0.80%, expected move 5.88%. The long put on DYAI below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.
Why this long put structure on DYAI specifically: DYAI IV at 20.50% is on the cheap side of its 1-year range, which favors premium-buying structures like a DYAI long put, with a market-implied 1-standard-deviation move of approximately 5.88% (roughly $0.05 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated DYAI expiries trade a higher absolute premium for lower per-day decay. Position sizing on DYAI should anchor to the underlying notional of $0.91 per share and to the trader's directional view on DYAI stock.
DYAI long put setup
The DYAI long put below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With DYAI near $0.91, the first option leg uses a $0.91 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed DYAI chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 DYAI shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $0.91 | N/A |
DYAI long put risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
DYAI long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on DYAI. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use long put on DYAI
Long puts on DYAI hedge an existing long DYAI stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying DYAI exposure being hedged.
DYAI thesis for this long put
The market-implied 1-standard-deviation range for DYAI extends from approximately $0.86 on the downside to $0.96 on the upside. A DYAI long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long DYAI position with one put per 100 shares held. Current DYAI IV rank near 0.80% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on DYAI at 20.50%. As a Healthcare name, DYAI options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to DYAI-specific events.
DYAI long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. DYAI positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move DYAI alongside the broader basket even when DYAI-specific fundamentals are unchanged. Long-premium structures like a long put on DYAI are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current DYAI chain quotes before placing a trade.
Frequently asked questions
- What is a long put on DYAI?
- A long put on DYAI is the long put strategy applied to DYAI (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With DYAI stock trading near $0.91, the strikes shown on this page are snapped to the nearest listed DYAI chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are DYAI long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the DYAI long put priced from the end-of-day chain at a 30-day expiry (ATM IV 20.50%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a DYAI long put?
- The breakeven for the DYAI long put priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current DYAI market-implied 1-standard-deviation expected move is approximately 5.88%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on DYAI?
- Long puts on DYAI hedge an existing long DYAI stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying DYAI exposure being hedged.
- How does current DYAI implied volatility affect this long put?
- DYAI ATM IV is at 20.50% with IV rank near 0.80%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.